WASHINGTON, February 3 - More than 170 million poor people worldwide receive regular payments from their governments, but the potential to use these payments to increase financial inclusion is largely untapped, according to "Banking the Poor via G2P Payments," a new report by CGAP, a microfinance group based at the World Bank, and the U.K.'s Department for International Development (DFID).

Fairmont St Andrews offers a Recipe for Romance Valentine's Day Package in Scotland

LONDON, February 3 - The government must provide better education and training opportunities to offenders on remand and those serving short term sentences to help them into meaningful employment, re-integrate them into society and cut reoffending.

BERLIN, February 2 - In partnership with leading organic companies from around the world, the international Nature & More Foundation has developed a web based sustainability navigator aimed at raising consumer awareness of sustainability. The 'Sustainability Flower' empowers the consumer to make an informed purchasing decision taking all relevant environmental and ethical implications into account.

BALTIMORE, February 2 - Celsis In Vitro, Inc. (Celsis IVT) announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical. The complaint alleges that certain processes and methods performed by XenoTech associated with its in vitro drug testing services and its pooled cryopreserved hepatocyte products, including CryoXTreme(TM), infringes one or more claims of U.S. Patent No. 7,604,929 (the '929 patent). The complaint also alleges that Sekisui Chemical and Sekisui Medical are inducing infringement of the '929 patent and seeks monetary damages and injunctive relief. Celsis IVT is represented by Jordan Sigale and Adam Kelly of Loeb & Loeb LLP.